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article under the CC BY-NC-ND licenseAbstract Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodi-
esterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients.
PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-
channel modulated pathways, and the L-cysteine/H2S pathway. PDE5 inhibitors exert their ef-
fect in muscle cells, nerve fibers, and interstitial cells (ICs). The use of PDE5 inhibitors led to
improvement in LUTS. This included urodynamic parameters. PDE5 inhibitors may play a signif-
icant role in LUTS due to their effect on the bladder rather than the prostate.
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(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lower urinary tract symptoms (LUTS), which may include
storage symptoms (urinary urgency, nocturia), or voiding
symptoms (urinary hesitancy, weak stream, straining, and
prolonged voiding), can have a significant negative impact
on quality of life (QoL) [1,2]. An estimated 45.2% of the
worldwide population is affected by atleast one urinary
symptom [3]. Out of 19,165 individuals surveyed in a cross-
sectional, population-based, multinational study conduct-
ed by Irwin and colleagues [4], 64.3% reported atleast one
urinary symptom, with nocturia being the most prevalent
(men, 48.6%; women, 54.5%). Similarly, in a national study
conducted by Herschorn and colleagues [5] in Canada on
1000 respondents, approximately half of the individuals
(43% of men and 57% of women) reported one or more
urinary symptoms, with nocturia being the most commonell.edu (B. Chughtai).
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(http://creativecommons.org/lisymptom (36%). A worldwide model estimates that by 2018,
an estimated 2.3 billion individuals will be affected by
atleast one urinary complaint (18.4% increase), with the
greatest increase expected in the developing regions [3].
Several medications are used to treat urinary symptoms,
including alpha blockers, anti-muscarinics, and phosphodi-
esterase type 5 (PDE5) inhibitors. Although the use of PDE5
inhibitors has been shown to improve LUTS, the clinical
mechanism of action of PDE5, if any, remains unclear. We
present data on the role of PDE5 in the bladder.
2. Evidence acquisition
A systematic literature search in PubMed was performed
between 1994 and 2014. The following terms were used:
PDE5 inhibitors, tadalafil, vardenafil, sildenafil. Relevant
citations from articles selected under the previously statednd SMMU.
n and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
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basic science studies were included. Each article’s title and
abstract were reviewed for their appropriateness and
relevance to the role of PDE5 inhibitors and their effect on
the bladder. Relevant articles were fully reviewed to assess
the design of the study and the amount of evidence, and
included in the final data acquisition.
3. Evidence synthesis
3.1. PDEs in the bladder
PDE5 plays a role in the smooth muscle cells (SMCs) of the
bladder, and the endothelium of blood vessels [6]. PDE5 has
been shown to have the highest expression in the muscular
cells in the lower urinary tract [7]. Study of Truss et al. [8] was
the first to demonstrate the presence of PDE 1, 2, 3, 4 and 5
isoenzymes in the human detrusor. PDE5 affects cGMP which
alters the intracellular calcium concentration [Ca], which is
the primary regulator of smooth muscle contractility [9].
3.2. Ex-vivo studies
Fibbi and colleagues [7] demonstrated that PDE5 had the
highest expression in the bladder as compared to the ure-
thra and prostate, and the greatest expression in the
muscular cells in the lower urinary tract. In their study
conducted on lower urinary tract tissues and SMCs cultured
from the urethra, prostate and bladder, the bladder neck
demonstrated very high PDE5 levels in the endothelial cells
of the blood vessels and in the SMCs of the muscular wall
and blood vessels. With the administration of vardenafil,
sodium nitroprusside (SNP)-induced growth inhibition in all
three tissue preparations was enhanced, with the maximum
anti-proliferative effects in the bladder neck (p < 0.01 vs.
urethra and prostate) [7].
PDE inhibitors mediate their effects via several secondary
signaling pathways. Oger and colleagues [10] demonstrated
that relaxation of the urinary bladder smooth muscle (UBSM)
by sildenafil involved the cAMP, cGMP and potassium-channel
modulated pathways, with contribution from nitric oxide
(NO) not being significant. Human bladder dome samples
were taken from 20 patients, who had no previous history of
bladder dysfunction and were undergoing cystectomy for
bladder cancer. Sildenafil was added to human bladder
strips, which were pre-contractedwith carbachol, inducing a
significant (p < 0.001) concentration dependent relaxation.
Administration of SNAP (NO donor) did not have a significant
relaxant effect and did not increase the effects of sildenafil
on the bladder. Administration of a guanylate cyclase inhib-
itor (ODQ), adenylate cyclase inhibitor (MDL-12,330A), and
Kþ-channel blockers, however, significantly (p < 0.001)
reduced sildenafil-induced relaxation in carbachol pre-
contracted detrusor strips.
PDE5 inhibitors modulate nervous signaling involved in
bladder contraction [11]. Xin and colleagues [12] demon-
strated that PDE inhibitors play an important role in nerve-
induced contractions of human UBSM and that Kþ-channels
mediate those effects. They investigated the role of BK (cal-
cium-activated potassium) channels in UBSM. A non-selective
PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX) was addedto humanUBSM-isolatedcells,which resulted in an increase in
the frequency of spontaneous transient outward currents
(STOCs), leading to UBSM cell membrane hyperpolarization
(p< 0.05). ThePDEblockadealso resulted inadecrease in the
intracellular calcium (Ca) levels and a suppression of the
myogenic (spontaneous phasic) and nerve-evoked contrac-
tions in human UBSM isolated strips (all p < 0.05).
A study focusing on the involvement of the H2S pathway
in the mechanism of action of PDE5 inhibitors concluded
that the L-cysteine/H2S pathway might be one possible
pathway through which PDE5 inhibitors exert their effects
on the bladder [13]. Fusco and colleagues [13] incorporated
sildenafil in their studies, which caused a significant
concentration-dependent increase in H2S production
compared to vehicle, along with a relaxation of the bladder
dome strips. Similarly, when inhibitors of cystathionine-b-
synthase (CBS) and cystathionine-g-lyase (CSE) (convertors
of L-cysteine to H2S) were used, relaxation in bladder strips
and rise in H2S both decreased.3.3. Animal studies
3.3.1. cAMP/cGMP and PDE5 inhibitors
PDE inhibitors mediate their effects via several secondary
signaling pathways, including cAMP and cGMP. Artim and
colleagues [14] suggested the presence of small amounts of
cGMP in rat bladder strips. SNAP (NO donor) was applied to
carbachol pre-contracted strips, resulting in a dose-
dependent reduction in the contractions. The application
of 8-bromo-cGMP (cGMP analog) also decreased the ampli-
tude and frequency of contractions, demonstrating the
involvement of cGMP in the NO pathway. The application of
Zaprinast to the bladder strips significantly (p < 0.005)
reduced the carbachol enhanced spontaneous contraction
amplitude, and when applied alone, also elicited a small
reduction in SCcarb frequency ([11.8  2.3]%, p < 0.05).
Another study also concluded that PDE5 inhibitors might
not act directly on DSM, but rather result in the accumulation
of cGMP in interstitial cells (ICs) [15]. Yanai and colleagues
[15] demonstrated that SNP (NO donor) increased the
amplitude and frequency of spontaneous phasic contractions
in a dose-dependent manner, and when applied in the pres-
ence of guanylate cyclase inhibitor (ODQ), still increased the
amplitude and frequency of the multibundle DSM sponta-
neous contractions. 8Br-cGMP however abolished/reduced
the amplitude and frequency of spontaneous contractions in
multibundle DSM, leading to the conclusion that the NO do-
nors had a cGMP-independent mechanism by which they
exerted excitatory effects on DSM spontaneous activity.With
the application of sildenafil, the amplitude and frequency of
the spontaneous contractions were either abolished or
reduced in 65% of multibundle DSM, whereas in single bundle
DSM, sildenafil had no effects on both the amplitude and
frequency of the spontaneous contractions [15].
However, it is not necessary that a rise in cGMP levels is
accompanied by relaxation of the bladder. Fujiwara and
colleagues [16] demonstrated that NO donors increased the
level of cGMP, but did not induce smooth muscle relaxation.
They reported positive cGMP-immunoreactivity in stromal
cells and nerve fibers and negative cGMP-immunoreactivity in
bladder smooth muscle bundles after exposure to NO donors.
Effect of PDE5 inhibitors in the bladder 35These three studies demonstrated the involvement of
cGMP in bladder physiology. While Artim et al. [14] and
Yanai et al. [15] described the involvement of cGMP in UBSM
contractility, Fujiwara et al. [16] proved that an increase in
cGMP does not induce smooth muscle relaxation. Qiu et al.
[17] and Werkstrom et al. [18] however completely con-
tradicted these findings, as their results put forth cAMP as
the primary mediator of UBSM contractility.
Qiu and colleagues [17] suggested that the cAMP
pathway was the primary mediator of smooth muscle
relaxation, with a rise in cGMP levels not being sufficient
independently, whereas Werkstrom and colleagues [18]
proposed that vardenafil-induced relaxation in rat bladder
was predominantly mediated by cAMP. They were able to
demonstrate that adding vardenafil to carbachol pre-
contracted detrusor strips resulted in dose-dependent
relaxation of the DSM, with max relaxation reaching
(91  4)% at 100 mmol/L.
3.3.2. Urothelium and PDE5 inhibitors
The urothelium, also known as the uro-epithelium, is the
innermost layer of the bladder [19]. It is involved in bladder
contraction and may be one possible site of action of the
PDE5 inhibitors. Animal studies conducted by Gillespie
et al. [20e22] have shown that the NO/cGMP pathway is
present in the urothelium and may play a role in the
maintenance of detrusor tone. Nerves present in bladder
interstitial cells produce cGMP which facilitates relaxation.
Therefore, PDE inhibitors may influence bladder function at
the level of the urothelium by inhibiting cGMP degradation.
3.3.3. Nerve fibers and PDE5 inhibitors
Behr-Roussel and associates [23] were the first to demon-
strate that vardenafil reduces both non-voiding contrac-
tions and bladder afferent nerve firing in unanesthetized,
decerebrate, spinal cord injured (SCI) rats. Fifteen female
SpragueeDawley rats with SCI were studied to assess the
use of vardenafil for reduction in bladder afferent nerve
firing and improvement in urodynamic parameters. After an
injection of vardenafil, there was a significant (p < 0.001)
reduction in the amplitude and frequency of non-voiding
contractions as compared to saline, along with a rapid
and significant (p < 0.001) drop in the mean spike rate of
bladder afferent nerve firing.
Tadalafil was also able to inhibit the activity of both
mechanosensitive afferent nerve fibers in two experiments
performed by Minagawa and colleagues [11]. In the first of
two experiments, single afferent activity (SAA) of both
single afferent fibers decreased significantly in a dose-
dependent manner after tadalafil administration. In the
second experiment, acrolein instillation did not signifi-
cantly change the SAA when pretreatment was carried out
with tadalafil. The suggestion that PDE5 inhibitors reduce
LUTS by acting in the neural pathways controlling the
bladder and not in the detrusor smooth muscle was further
reinforced by Artim and colleagues [24] in their study on
the rat urinary bladder.
In an animal model of neurogenic bladder, Mirzaii-Dizgah
and Salmanyan [25] assessed 40 male rats divided into five
equal groups. SCI was induced in all but the sham group,
and renal system and motor functions were evaluated 28
days following injury. Rats were given statins, PDE5inhibitors (sildenafil and tadalafil), or saline. PDE5 in-
hibitors improved motor function, but did not impact renal
function.
3.3.4. Bladder oxygenation and PDE5 inhibitors
The role of PDE5 inhibitors in bladder oxygenation was
investigated by Morelli and colleagues [26], who demon-
strated that vardenafil significantly reduced bladder hyp-
oxia using an animal model of naturally occurring
overactive bladder. The effects of vardenafil administration
on bladder oxygenation in spontaneously hypertensive rats
(SHRs) were investigated by the administration of a single
dose of vardenafil (10 mg/kg) to SHRs 90 min before they
were sacrificed. It was observed that vardenafil not only
relaxed the muscular wall, but also improved urinary
vesicle blood perfusion. Similar results were obtained in a
study conducted by Nomiya and colleagues [27], who
administered tadalafil to rats that had induced chronic
bladder ischemia. Apart from preventing neo-intimal for-
mation and luminal occlusion, tadalafil significantly
improved all functional and morphological parameters and
eventually decreased bladder overactivity.3.4. Human studies
Open-label studies were performed in men to demonstrate
the efficacy of PDE5 inhibitors for the treatment of LUTS.
Sairam and colleagues [28] reported the results of their
open-label study, which evaluated the possible relationship
between erectile dysfunction (ED) and LUTS. They
demonstrated that treatment of ED with sildenafil
improved LUTS, and proposed that the NO/sildenafil
pathway could be involved in smooth muscle relaxation in
the lower urinary tract. A total of 112 men were enrolled in
the study. Participants were treated with oral sildenafil and
were assessed after 1 and 3 months using international
prostate symptom score (IPSS) and QoL questionnaires.
LUTS were classified as mild, moderate, or severe. After 3
months of treatment, all LUTS that were initially classified
as severe in intensity became moderate, 60% of LUTS that
were moderate in intensity became mild, and 18% of LUTS
that were mild became moderate. The QoL had also
improved. A similar result was obtained by Mulhall and
colleagues [29] in their open-label study to assess the ef-
fect of Viagra on LUTS. They demonstrated that sildenafil
had a positive effect of LUTS, suggesting that sildenafil
mediates its effects through bladder neck/prostatic smooth
muscle relaxation. A total of 48 men were enrolled in the
study, all of whom had an initial IPSS score of greater than
10. A 100 mg dose of sildenafil was administered to all the
patients, with a mean number of uses of 2.0  0.6 per
week. IPSS questionnaire was filled atleast 3 months after
the commencement of sildenafil and was then compared to
the pre-treatment IPSS questionnaire. There was a mean
improvement of 4.6 points (p Z 0.013) in IPSS and a mean
improvement of 1.4 points (pZ 0.025) in QoL score. Of the
48 participants, 60% displayed improvement in IPSS score,
35% had atleast a 4-point improvement in IPSS score, and 1%
had IPSS score <7 by the end of the treatment. Both of
these open-label studies assessed the efficacy of PDE5 in-
hibitors in the bladder, paving the way for the subsequent
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provided further evidence to corroborate these claims.
McVary and associates [30] conducted a 12-week,
double-blind, placebo controlled study of sildenafil for the
treatment of men with both ED and LUTS. One hundred and
eighty-five men receiving 50 mg daily of sildenafil reported
significant improvements in IPSS when compared to 180
men receiving placebo (6.32 vs. 1.93, p < 0.0001) and
mean IPSS QoL score vs. placebo (0.97 vs. 0.29,
p < 0.0001). No differences were seen in urinary flow rates
(Qmax, p Z 0.8) between the two groups. Roehrborn and
colleagues [31] similarly conducted a study in 1058 men
with LUTS secondary to benign prostatic hyperplasia (BPH).
Following a 4-week placebo run-in period, participants
were randomized to receive once daily treatment with
placebo or tadalafil (2.5, 5, 10 or 20 mg) for 12 weeks.
Significant improvements were observed in IPSS irritative
and obstructive subscores for participants taking 5, 10, and
20 mg tadalafil. The 5 mg dose was noted to provide the
best risk-benefit profile.
In a double-blind study, Gacci and colleagues [32]
assessed the role of vardenafil in continence recovery
after bilateral nerve sparing radical prostatectomy (BNS-
RP). Thirty-nine men with prostate cancer were enrolled
and assigned to vardenafil on demand, vardenafil nightly,
or placebo. Urinary bother and urinary function were
assessed using the University of CaliforniaeLos Angeles
Prostate Cancer Index questionnaire preoperatively and at
1, 3, 6, 9, 10, and 12 months post-operatively. Significant
improvements in urinary bother and urinary function were
observed after nightly and on-demand administration of
vardenafil at 12 month follow-up when compared to pla-
cebo. Daily vardenafil administration yielded better re-
sults than on-demand administration in regard to
continence rates.
Urodynamic studies are beneficial in monitoring LUTS
and the response of LUTS to treatment. In a single center,
randomized, double-blind, placebo controlled trial, Gacci
and colleagues [33] assessed changes in urodynamic indices
following vardenafil administration in 25 patients with SCI.
Three urodynamic parameters were assessed: maximum
detrusor pressure, maximum cystometric capacity, and
detrusor overactivity volume. One urodynamic assessment
was performed at baseline and a second one was performed
3 h after the administration of 20 mg vardenafil in 15 cases
and placebo in 10 cases. Urodynamic parameters were un-
changed for those who received placebo. Vardenafil
administration produced significant improvements. Varde-
nafil reduced maximum detrusor pressure with a mean
decrease of 12% (p < 0.001), increased mean maximum
cystometric capacity by 17% (p < 0.001), and increased
detrusor overactivity volume by 25% (p < 0.0001).
A similar improvement in urodynamic indices was
observed by Taie and colleagues [34], who performed a
pilot study to assess the impact of single dose oral tadalafil
on 20 patients with supra sacral spinal cord injury. After an
initial baseline urodynamic assessment, all patients were
administered a single dose of 20 mg tadalafil. A second
urodynamic test was performed after 1 h and urodynamic
indices were then compared. Improvements were observed
in bladder compliance, bladder capacity, maximum voiding
detrusor pressure, and maximum detrusor filling pressure.4. Conclusion
The prevalence of LUTS increases with age, and its complex
pathophysiology can make treatment difficult. Recently,
the bladder has become the target of several studies as the
focus of research has shifted from a prostate-centered
approach to LUTS treatment. The NO/cGMP and cAMP
pathways appear to be involved in the pathophysiology of
LUTS. Several theories, however, remain regarding the
mechanism of action of PDE inhibitors. Studies have shown
the involvement of the cAMP, cGMP, Kþ-channel modulated
pathways and the L-cysteine/H2S pathway as possible
pathways through which PDE5 inhibitors exert their effects
on the bladder. Animal models have also produced con-
flicting results as to the location of the bladder where the
PDE5 inhibitors exert their effects, whether it is the muscle
cells, nerve fibers, or interstitial cells. Human trials and
urodynamic studies involving the use of PDE5 inhibitors
have however provided encouraging results in the treat-
ment of LUTS. Further studies are therefore required to
definitively identify the underlying processes associated
with the use of PDE5 inhibitors in order to effectively
manage conditions related to the lower urinary tract.Conflicts of interest
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